PEPFAR's annual planning process is done either at the country (COP) or regional level (ROP).
PEPFAR's programs are implemented through implementing partners who apply for funding based on PEPFAR's published Requests for Applications.
Since 2010, PEPFAR COPs have grouped implementing partners according to an organizational type. We have retroactively applied these classifications to earlier years in the database as well.
Also called "Strategic Areas", these are general areas of HIV programming. Each program area has several corresponding budget codes.
Specific areas of HIV programming. Budget Codes are the lowest level of spending data available.
Expenditure Program Areas track general areas of PEPFAR expenditure.
Subdivisions of Program Areas, these track general higher level sub-classifications of expenditure.
Subdivisions of Major categories, these are the most detailed expenditure data.
Cross-cutting attributions are areas of PEPFAR programming that contribute across several program areas. They contain limited indicative information related to aspects such as human resources, health infrastructure, or key populations programming. However, they represent only a small proportion of the total funds that PEPFAR allocates through the COP process. Additionally, they have changed significantly over the years. As such, analysis and interpretation of these data should be approached carefully. Learn more
PEPFAR sets targets using the Monitoring, Evaluation, and Reporting (MER) System - documentation for which can be found on PEPFAR's website at https://www.pepfar.gov/reports/guidance/. As with most data on this website, the targets here have been extracted from the COP documents. Targets are for the fiscal year following each COP year, such that selecting 2016 will access targets for FY2017. This feature is currently experimental and should be used for exploratory purposes only at present.
Years of mechanism: 2010
NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.
Tuberculosis (TB) is a leading cause of mortality among HIV infected persons in Botswana. Traditional TB testing (smear microscopy) has poor sensitivity in persons with HIV. Gene Xpert, a new WHO recommended TB diagnostic technology, has increased sensitivity when compared to microscopy, especially among persons with HIV. XPRES (Xpert Package Rollout Evaluation) is an operational research study conducted by CDC Botswana, partnering with the GoB.
The main goal of the XPRES study is to compare sensitivity of the Xpert and microscopy algorithms and their impact on TB disease burden in Botswana. XPRES is taking place in 11 districts with the highest HIV and TB rates in Botswana. Study participants include HIV-positive persons who present at HIV clinics for care and treatment. XPRES has a complete M&E component, involving quarterly lab supervision visits and routine analysis of data exported from the Xpert machine.
Preliminary results from this study, including lessons learned about Xpert placement, operation and M&E, have informed the GoB in their own current efforts with Xpert, and findings of the study will continue to guide the national rollout. At the close of this study, CDC will continue to provide guidance, but the responsibility and funding of this continued effort will be with the GoB; GoB has already started to fund and implement this effort by introducing Xpert at 12 sites over the past 7 months.
Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.
This mechanism has no published performance targets or indicators.